Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) for Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
March 25th, 2008
Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) announced the publication of updated results of the Phase I/II clinical trial of the combination therapy VELCADE, melphalan and prednisone (VcMP) in newly diagnosed multiple myeloma patients, who were ineligible for stem cell transplantation. Results of this study included one of the highest reported complete remission (CR) rates, which is an important indicator for long-term survival, and the highest three- year survival rate reported in the non-transplant setting. These results provided the basis for the Phase III VISTA trial. The Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in...
Source: Cancer Weekly (2008-03-25)
|
